ScreenerHero

PYXSPyxis Oncology Inc. Common Stock

NAS · US · Healthcare · Biotechnology · pyxisoncology.com
3.080USD-8.61%Mkt Cap: 256.90M $P/E: —

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consist…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap256.90M $
Enterprise Value245.07M $
Revenue (TTM)11.04M $
Gross Profit11.47M $
Net Income (TTM)-79.62M $
Revenue/Share0.1750 USD
Last Price3.080 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees56
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.77
PEG—
EV/EBITDA-2.87
EV/Revenue22.20
P/S23.58
P/B6.27
EPS (TTM)-1.30
EPS (Forward)-1.13
52W Range
1.03045% of range5.550
52W High5.550 USD
52W Low1.030 USD
Profitability
Gross Margin82.77%
Oper. Margin-812.74%
EBITDA Margin0.00%
Profit Margin-574.55%
ROE-149.08%
ROA-87.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-63.50M $
CapEx (TTM)9.00K $
FCF Margin-210.06%
FCF Yield-9.03%
Net Debt-15.16M $
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity0.35
Current Ratio1.34
Quick Ratio1.20
Book Value/Sh0.4980 USD
Cash/Share0.3960 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.222 USD
Upside (mean)+134.5%
Target Range5.000 USD – 12.00 USD
$5.000+134.5% to mean$12.00
# Analysts9
Ownership
Shares Out.83.41M
Float49.56M
Insiders13.53%
Institutions42.50%
Short Interest
Short Ratio3.2d
Short % Float8.91%
Short % Out.6.59%
Shares Short4.17M
Short (prev mo.)2.29M
Technical
SMA 502.646 (+16.4%)
SMA 2002.323 (+32.6%)
Beta1.32
S&P 52W Chg18.16%
Avg Vol (30d)1.35M
Avg Vol (10d)2.09M
Technical Indicators
RSI (14)52.3
MACD0.1671
MACD Signal0.2041
MACD Hist.-0.0370
BB Upper3.781 USD
BB Middle3.084 USD
BB Lower2.388 USD
BB Width45.19%
ATR (14)0.4169 USD
Vol Ratio (20d)0.40x